QR-Code

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy

Background. The wide availability of monoclonal antibodies for the add-on therapy of severe asthma currently allows for the personalization of biologic treatment by selecting the most appropriate drug for each patient. However, subjects with overlapping allergic and eosinophilic phenotypes can be of...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Corrado Pelaia, Claudia Crimi, Santi Nolasco, Giovanna Elisiana Carpagnano, Raffaele Brancaccio, Enrico Buonamico, Raffaele Campisi, Claudia Gagliani, Vincenzo Patella, Girolamo Pelaia, Giuseppe Valenti, Nunzio Crimi
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2021-12-01
Schriftenreihe:Biomedicines
Schlagworte:
severe asthma
allergy
eosinophils
omalizumab
benralizumab
switching
Online-Zugang:https://www.mdpi.com/2227-9059/9/12/1822
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge